IP Library › Granted Patent US 12,533,400
Granted Patent B2
US 12,533,400 · App. 19/254,402 · Granted Jan 27, 2026

Zonal and targeted methods and uses for treating a chronic post-traumatic headache associated with a post-traumatic stress disorder

Inventor: William J. Binder (Beverly Hills, CA)
Assignee: Miotox, LLC
A61K38/4893A61K9/0019A61P25/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,533,400
App. No.
19/254,402
Granted
Jan 27, 2026
Kind
B2
Abstract

The present specification discloses methods for treating a PTSD. The methods comprise extramuscularly administering a Botulinum toxin to an individual in one or more areas of a fronto-fascial layer located in a frontal head region, one or more areas of a temporoparietal-fascial layer located in a temporal head region, and one or more areas of an occipito-fascial layer located in an occipital head region. The methods further comprise extramuscularly administering a Botulinum toxin to one or more nerve exit points and/or one or more subcutaneous locations in the head and neck and/or one or more sites of an epicranial aponeurosis. The methods further comprise intramuscularly administering a Botulinum toxin to one or more locations within the left and right Splenius Capitis muscle, the left and right Masseter muscles, the left and right Trapezius muscles, or any combination thereof.

Claims (28)

1 . A method for treating a chronic post-traumatic headache associated with a post-traumatic stress disorder, the method comprising extramuscularly administering a Botulinum toxin to an individual in

one or more areas of a fronto-fascial layer located in a frontal head region of the individual, the one or more areas of the fronto-fascial layer including a left frontal nerve cluster zone and a right frontal nerve cluster zone, the left frontal nerve cluster zone located in a left portion of the frontal head region directly over and superficial to the left frontalis muscle and the right frontal nerve cluster zone located in a right portion of the frontal head region directly over and superficial to the right frontalis muscle, wherein the left frontal nerve cluster zone is defined by a closed area having a first left frontal horizonal boundary, a second left frontal horizonal boundary, a first left frontal vertical boundary, and a second left frontal vertical boundary, the first left frontal horizonal boundary following a scalp line and being located about 4.5 cm to 7.5 cm above and parallel to a left supraorbital ridge, the second left frontal horizontal boundary being located about 2 cm to about 3 cm below the first left frontal horizontal boundary, the first left frontal vertical boundary being located about 0.5 cm to about 1 cm laterally left from the midline of the forehead, and the second left frontal vertical boundary being located in-line with a medial inferior edge of the left superior orbital ridge, and wherein the right frontal nerve cluster zone is defined by a closed area having a first right frontal horizonal boundary, a second right frontal horizonal boundary, a first right frontal vertical boundary, and a second right frontal vertical boundary, the first right frontal horizonal boundary following a scalp line and being located about 4.5 cm to 7.5 cm above and parallel to a right supraorbital ridge, the second right frontal horizontal boundary being located about 2 cm to about 3 cm below the first right frontal horizontal boundary, the first right frontal vertical boundary being located about 0.5 cm to about 1 cm laterally right from the midline of the forehead, and the second right frontal vertical boundary being located in-line with a medial inferior edge of the right superior orbital ridge, wherein at least 25 units of the Botulinum toxin are administered to the left frontal nerve cluster zone and at least 25 units of the Botulinum toxin are administered to the right frontal nerve cluster zone,

one or more areas of a temporoparietal-fascial layer located in a temporal head region of the individual, the one or more areas of the temporoparietal-fascial layer including a left temporal nerve cluster zone and a right temporal nerve cluster zone, the left temporal nerve cluster zone located in a left temporal head region directly over and superficial to the left temporalis muscle and the right temporal nerve cluster zone located in a right temporal head region directly over and superficial to the right temporalis muscle, wherein the left temporal nerve cluster zone is defined by a closed area having a first left temporal horizonal boundary, a second left temporal horizonal boundary, a first left temporal vertical boundary, and a second left temporal vertical boundary, the first left temporal horizonal boundary being in-line with and following a curvature of a left superior temporal line, the second left temporal horizonal boundary being located about 1.5 cm to about 2 cm above and following a superior aspect of a left zygomatic arch and a curvature of an outside edge of a left crus and a superior portion of a left helical rim of a left ear, the first left temporal vertical boundary being positioned in line with an outer dorsal edge of the left helical rim of the left ear, and the second left temporal vertical boundary being positioned in line with a ventral edge of a head of a left condylar process of a left mandibular ramus, and wherein the right temporal nerve cluster zone is defined by a closed area having a first right temporal horizonal boundary, a second right temporal horizonal boundary, a first right temporal vertical boundary, and a second right temporal vertical boundary, the first right temporal horizonal boundary being in-line with and following a curvature of a right superior temporal line, the second right temporal horizonal boundary being located about 1.5 cm to about 2 cm above and following a superior aspect of a right zygomatic arch and a curvature of an outside edge of a right crus and a superior portion of a right helical rim of a right ear, the first right temporal vertical boundary being positioned in line with an outer dorsal edge of the right helical rim of the right ear, and the second right temporal vertical boundary being positioned in line with a ventral edge of a head of a right condylar process of a right mandibular ramus, and

one or more areas of an occipito-fascial layer located in an occipital head region of the individual, the one or more areas of the occipito-fascial layer including a left occipital nerve cluster zone and a right occipital nerve cluster zone, the left occipital nerve cluster zone located in a left portion of the occipital head region directly over and superficial to the left occipitalis muscle and the right occipital nerve cluster zone located in a right portion of the occipital head region directly over and superficial to the right occipitalis muscle, wherein the left occipital nerve cluster zone is defined by a closed area having a first left occipital horizonal boundary, a second left occipital horizonal boundary, a first left occipital vertical boundary, and a second left occipital vertical boundary, the first left occipital horizonal boundary being located about 3 cm above and following a left superior aspect of a nuchal ridge, the second left occipital horizontal boundary being located in-line with the left superior aspect of the nuchal ridge, the first left occipital vertical boundary being located about 0.5 cm to about 1 cm laterally left from an external occipital crest and the second left occipital vertical boundary being positioned in line with a left mastoid process and a dorsal portion of a left superior temporal line, and wherein the right occipital nerve cluster zone is defined by a closed area having a first right occipital horizonal boundary, a second right occipital horizonal boundary, a first right occipital vertical boundary, and a second right occipital vertical boundary, the first right occipital horizonal boundary being located about 3 cm above and following a right superior aspect of the nuchal ridge, the second right occipital horizontal boundary being located in-line with the right superior aspect of the nuchal ridge, the first right occipital vertical boundary being located about 0.5 cm to about 1 cm laterally right from the external occipital crest and the second right occipital vertical boundary being positioned in line with a right mastoid process and a dorsal portion of a right superior temporal line, wherein at least 30 units of the Botulinum toxin are administered to the left occipital nerve cluster zone and at least 30 units of the Botulinum toxin are administered to the right occipital nerve cluster zone,

wherein a unit of the Botulinum toxin is defined as the potency or activity ascribed to a unit of onabotulinumtoxinA,

wherein a unit of incobotulinumtoxinA and a unit of prabotulinumtoxinA is equivalent to the unit of onabotulinumtoxinA, and wherein a unit of abobotulinumtoxinA is about 2.5 to about 3 times more than the unit of onabotulinumtoxinA, and

wherein the chronic post-traumatic headache is a mild chronic post-traumatic headache, a moderate chronic post-traumatic headache, or a severe chronic post-traumatic headache.

2 . The method of claim 1 , wherein 50 units to 60 units of the Botulinum toxin are administered within the fronto-fascial layer, wherein 5 units of the Botulinum toxin is administered to each of one or more sites within the one or more areas of the fronto-fascial layer.

3 . The method of claim 1 , wherein 40 units to 70 units of the Botulinum toxin are administered within the temporoparietal-fascial layer, wherein 5 units of the Botulinum toxin is administered to each of one or more sites within the one or more areas of the temporoparietal-fascial layer.

4 . The method of claim 1 , wherein 60 units to 110 units of the Botulinum toxin are administered to one or more sites within each of the one or more areas of the occipito-fascial layer, wherein 5 units of the Botulinum toxin is administered to each of one or more sites within the one or more areas of the occipito-fascial layer.

5 . The method of claim 1 , wherein 25 units to 30 units of the Botulinum toxin are administered to the left frontal nerve cluster zone and 25 units to 30 units of the Botulinum toxin are administered to the right frontal nerve cluster zone, wherein 5 units of the Botulinum toxin is administered to each of the one or more sites within the left frontal nerve cluster zone and the right frontal nerve cluster zone.

6 . The method of claim 1 , wherein 20 units to 35 units of the Botulinum toxin are administered to the left temporal nerve cluster zone and 20 units to 35 units of the Botulinum toxin are administered to the right temporal nerve cluster zone, wherein 5 units of the Botulinum toxin is administered to each of one or more sites within the left temporal nerve cluster zone and the right temporal nerve cluster zone.

7 . The method of claim 1 , wherein 30 units to 55 units of the Botulinum toxin are administered to the left occipital nerve cluster zone and 30 units to 55 units of the Botulinum toxin are administered to the right occipital nerve cluster zone, wherein 5 units of the Botulinum toxin is administered to each of the one or more sites within the left occipital nerve cluster zone and the right occipital nerve cluster zone.

8 . The method of claim 1 , further comprising extramuscularly administering a Botulinum toxin to one or more nerve exit points in the head and neck.

9 . The method of claim 8 , wherein the Botulinum toxin is extramuscularly administered to one or more nerve exit points of a Supraorbital nerve, a Supratrochlear nerve, or any combination thereof.

10 . The method of claim 8 , wherein the Botulinum toxin is extramuscularly administered to a location along a medial branch of a Supratrochlear nerve located subcutaneously above the central part of the procerus muscle.

11 . The method of claim 8 , wherein the Botulinum toxin is extramuscularly administered to an exit location of the Greater Auricular nerve located subcutaneously above the posterior edge of the midpoint of the left Sternocleidomastoideole and to an exit location of the Greater Auricular nerve located subcutaneously above the posterior edge of the midpoint of the right Sternocleidomastoideole.

12 . The method of claim 11 , further comprising extramuscularly administered of the Botulinum toxin to a location along the Greater Auricular nerve located subcutaneously above a position midway between the mastoid process and a line drawn at the midpoint of the left Sternocleidomastoideole and to a location along the Greater Auricular nerve located subcutaneously above a position midway between the mastoid process and a line drawn at the midpoint of the right Sternocleidomastoideole.

13 . The method of claim 1 , further comprising extramuscularly administering a Botulinum toxin to one or more sites along a Supraclavicular nerve, a Cervical Nerve Plexus, or any combination thereof.

14 . The method of claim 13 , wherein the one or more sites along the Supraclavicular nerve include one or more subcutaneous sites located at an apical ridge of a superior portion of a left Trapezius muscle or one or more subcutaneous sites located at an apical ridge of a superior portion of a right Trapezius muscle.

15 . The method of claim 13 , wherein the one or more sites along the Cervical Nerve Plexus include a subcutaneous site located above a cervical vertebrae insertion of a left Longissimus capitis muscle, a subcutaneous site located above a cervical vertebrae insertion of a left Longissimus cervicis muscle, a subcutaneous site located above a cervical vertebrae insertion of a right Longissimus capitis muscle, or a subcutaneous site located above a cervical vertebrae insertion of a right Longissimus cervicis muscle.

16 . The method of claim 1 , further comprising one or more additional administration sites peripheral to the left and right frontal nerve cluster zones (LZI and RZI), the left and right temporal nerve cluster zones (LZII and RZII), and/or the left and right occipital nerve cluster zones (LZIII and RZIII).

17 . The method of claim 1 , further comprising extramuscularly administering a Botulinum toxin to one or more sites of an epicranial aponeurosis.

18 . The method of claim 1 , further comprising intramuscularly administering a Botulinum toxin to one or more locations within the left and right Splenius Capitis muscle, the left and right Masseter muscles, the left and right Trapezius muscles, or any combination thereof.

19 . The method of claim 18 , wherein the one or more locations of the left and right Splenius Capitis muscles include an intramuscular site located above a soft triangular depression cranially to a superior edge of a left Splenius Capitis muscle or an intramuscular site located above a soft triangular depression cranially to a superior edge of a right Splenius Capitis muscle.

20 . The method of claim 18 , wherein the one or more locations of the left and right Masseter muscles include one or more intramuscular sites located above a left masseter muscle near an angle of a left mandibular ramus or one or more intramuscular sites located above a right masseter muscle near an angle of a right mandibular ramus.

21 . The method of claim 18 , wherein the one or more locations of the left and right Trapezius muscles include one or more intramuscular sites located at an apical ridge of a superior portion of a left Trapezius muscle or one or more intramuscular sites located at an apical ridge of a superior portion of a right Trapezius muscle.

22 . The method of claim 1 , wherein the chronic post-traumatic headache is a chronic post-traumatic headache with migraine features or a chronic post-traumatic migraine.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 28, 2025
From: BINDER, WILLIAM J.
To: MIOTOX, LLC
Reel/Frame 071849/0377 →
Continuity (4)
Continuation 18978955 · Dec 12, 2024
Continuation 17338388 · Jun 3, 2021
Provisional Application 63034215 · Jun 3, 2020
Related Publication 20250325641A1 · Oct 23, 2025
References Cited (112)
US 5714468A · Binder · 1998 [cited by applicant]
US 7655244B2 · Blumenfeld · 2010 [cited by applicant]
US 7704511B2 · Turkel · 2010 [cited by applicant]
US 7749515B2 · Blumenfeld · 2010 [cited by applicant]
US 8420106B1 · Binder · 2013 [cited by examiner]
US 8491917B1 · Binder · 2013 [cited by applicant]
US 8617569B2 · Binder · 2013 [cited by applicant]
US 8722060B2 · Binder · 2014 [cited by applicant]
US 8883143B2 · Binder · 2014 [cited by applicant]
US 9764009B2 · Abel · 2017 [cited by applicant]
US 10111938B2 · Blumenfeld · 2018 [cited by applicant]
US 10201497B2 · Binder · 2019 [cited by applicant]
US 10406213B2 · Turkel · 2019 [cited by applicant]
US 10456455B2 · Abel · 2019 [cited by applicant]
US 11077174B2 · Abel · 2021 [cited by applicant]
US 11419922B2 · Finzi · 2022 [cited by applicant]
US 20050147626A1 · Blumenfeld · 2005 [cited by applicant]
US 20050191320A1 · Turkel · 2005 [cited by applicant]
US 20080069841A1 · Panjwani · 2008 [cited by applicant]
US 20080279895A1 · Blumenfeld · 2008 [cited by applicant]
US 20090252764A1 · Blumenfeld · 2009 [cited by applicant]
US 20090263426A1 · Turkel · 2009 [cited by applicant]
US 20100189655A1 · Turkel · 2010 [cited by applicant]
US 20110200639A1 · Blumenfeld · 2011 [cited by applicant]
US 20120315297A1 · Abel · 2012 [cited by applicant]
US 20150132282A1 · Finzi · 2015 [cited by applicant]
US 20150231068A1 · Binder · 2015 [cited by applicant]
US 20170088612A1 · Bigal · 2017 [cited by applicant]
US 20190060423A1 · Blumenfeld · 2019 [cited by applicant]
US 20190240299A1 · Blumenfeld · 2019 [cited by applicant]
US 20190256607A1 · Sun · 2019 [cited by applicant]
US 20200000892A1 · Turkel · 2020 [cited by applicant]
CA 2596366A1 · 2006 [cited by applicant]
WO 1995030431A1 · 1995 [cited by applicant]
WO 2004084839A2 · 2004 [cited by applicant]
WO 2005084705A1 · 2005 [cited by applicant]
WO 2006083455A1 · 2006 [cited by applicant]
WO 2010135538A1 · 2010 [cited by applicant]
WO 2013137969A1 · 2013 [cited by applicant]
WO 2018175696A1 · 2018 [cited by applicant]
Iljazi, Afrim, et al. “Post-traumatic stress disorder after traumatic brain injury—a systematic review and meta-analysis.” Neurological sciences 41.10 (2020): 2737-2746. (Year: 2020). [cited by examiner]
Advanced Anatomy 2nd Ed; https://pressbooks.bccampus.ca/advancedanatomy1sted/chapter/muscles/#:-:text=Epicranial% 20Aponeurosis%20also%20referred%20to,bones%20to%20the%20lambdoid%20suture; Accessed Dec. 22, 2022 (Year: … [cited by applicant]
Albanese, Terminology for Preparations of Bolulinum Neuroloxins: What a Difference a Name Makes, JAMA 305:89-90 (2011). [cited by applicant]
Allergan, BOTOX Product Information (url: https://hcp.boloxcosmetic.com/) (Downloaded 2016). [cited by applicant]
Allergan, Injection Workbook for Chronic Migraine (2015). [cited by applicant]
Anonymous, PTSD—Does anyone else deal with chronic daily headache from PTSD, how do you treat them? URL: rittps://www.drugs.com/answers/post-traumatic-stress-disorder-does-anyone-else-408139.html (Downloaded Dec. 1, 201… [cited by applicant]
Arcilla, et al., Neuroanatomy, Unmyelinated Nerve Fibers, pp. 7, StatPearls, (2023). [cited by applicant]
Argyriou, et al., OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine, Toxins 14(12): 847-857 (2022). [cited by applicant]
Bach-Rojecky, et al., Central origin of the antinociceptive action of botulinum toxin type A, Pharmacology, Biochemistry and Behavior 94: 234-238 (2009). [cited by applicant]
Bahl, et al., Local Anethesia in Dentistry, Anesth Prog 51:138-142 (2004). [cited by applicant]
Barba, et al., Learning Curve of Botulinum Toxin Bladder Injection for the Treatment of Refractory Overactive Bladder, Int. J. Womens Health 14: 1-7 (2022). [cited by applicant]
Binder, et al., Botulinum toxin type A {BOTOX) for treatment of migraine headaches: An open-label study, btolaryngology—Head and Neck Surgery 123: 669-676 (2000). [cited by applicant]
Binder, et al., Treatment of migraine headache with botulinum toxin type A, Facial Plastic Surgery Clinics of North merica 11: 465-475 (2003). [cited by applicant]
Biologydictionary.net Editors. “Occipital Bone.” Biology Dictionary, Biologydictionary.net, Jun. 11, 2020, https://biologydictionary.net/ occipital-bone/. (2020). [cited by applicant]
Biologydictionary.net Editors. “Zygomatic Arch.” Biology Dictionary, Biologydictionary.net, Apr. 5, 2017, https://biologydictionary.net/zygomatic-arch/. (2017). [cited by applicant]
Blumenfeld, et al., Insights into the Functional Anatomy Behind the PREEMPT njection Paradigm: Guidance on Achieving Optimal butcomes, Headache 57:766-777 (2017). [cited by applicant]
Blumenfeld, et al., Method of Injection of OnabotulinumtoxinA for Chronic Migraine: A Safe, Well-Tolerated, and ffective Treatment Paradigm Based on the PREEMPT Clinical Program, Headache 50: 1406-1418 {2010). [cited by applicant]
Blumenfeld, et al., Procedures for Administering Botulinum Toxin Type A or Migraine and Tension-type Headache, Headache 43:884-891 (2003). [cited by applicant]
Blumenfeld, et al., The Emerging Role of Botulinum Toxin A in Headache Prevention, Operative Techniques in Ptolaryngology-Head and Neck Surgery 15(2):90-96 (2004). [cited by applicant]
Bordoni B, Varacallo M. Anatomy, Head and Neck, Sternocleidomastoideole. [Updated Apr. 5, 2022]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; Jan. 2022-. Available from: https://www.ncbi.nlm.n… [cited by applicant]
Breeland G, Aktar A, Patel BC. Anatomy, Head and Neck, Mandible. [Updated Jun. 1, 20221]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; Jan. 2022 -. Available from: https://www.ncbi.nlm.nih.gov… [cited by applicant]
Brown TM, Drake TM, Krishnamurthy K. Anatomy, Head and Neck, Procerus Muscle. [Updated Aug. 8, 2022]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; Jan. 2022-. Available from: https://www.ncbi.… [cited by applicant]
Burstein, et al., Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review, Headache, 60:1259-1271 (2020). [cited by applicant]
Channell, et al., Management of Chronic Posttraumatic Headache: A Multidisciplinary Approach, JADA 109: 509-513 (2009). [cited by applicant]
Choi, II, and Sang Ryong Jeon. “Neuralgias of the head: occipital neuralgia.” Journal of Korean Medical Science 31.4 (2016): 479-488. (Year: 2016). [cited by applicant]
Crawford, et al., Functional Anatomy of the Sensory Nervous System: Updates from the Neuroscience Bench, 48 (1):174-189 (2020). [cited by applicant]
Day, Sphenopalantine Ganglion Analgesia, Curr Rev Pain. 3:342-347 (1999). [cited by applicant]
Gatt, et al, PM. Anatomy, Fascia Layers. Jul. 25, 2022. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; Jan. 2023-. PMID: 30252294. (2022). [cited by applicant]
Gerwin, Treatment of Chronic Migraine Headache with OnabotulinumtoxinA, Curr Rev Pain. 15: 336-338 (2011). [cited by applicant]
Ginsberg, et al., Great Auricular Nerve: Anatomy and Imaging in a Case of Perineural Tumor Spread, Am. J. Neuroradiol. 21: 568-571 (2000). [cited by applicant]
Glenesk, et al., Anatomy, Head and Neck, Posterior Cervical Nerve Plexus. [Updated Jul. 25, 2022]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; Jan. 2022-. Available from: https://www.ncbi.nlm… [cited by applicant]
Glenesk, et al., Anatomy, Head and Neck, Posterior Cervical Nerve Plexus, StatPearls, pp. 4 (2023). [cited by applicant]
Goadsby, Sphenopalatine (pterygopalatine) ganglion stimulation and cluster headache: New hope for ye who enter riere, Cephalagia 33: 813-815 (2013). [cited by applicant]
Greenberg, et al, Anatomy, Head and Neck: Auriculotemporal Nerve, StatPearls, pp. 4 (2023). [cited by applicant]
Grujici, Occipital Nerves, pp. 4, KenHub at https://www.kenhub.com/en/library/anatomy/occipital-nerves (2023). [cited by applicant]
Huff, et al., Neuroanatomy, Cranial Nerve 5 (Trigeminal), StatPearls, pp. 7 (2022). [cited by applicant]
Iyengar, et al., CGRP and the Trigeminal System in Migraine, Headache 59: 659-681 (2019). [cited by applicant]
Kaye, et al “Botox for migraine headaches and facial pain.” Diagnosis and Management of Head and Face Pain: A Practical Approach (2018): 171-186. (2018). [cited by applicant]
Ko, et al., Retrospective Observational Study of Treatment Patterns and Efficacy of onabotulinumtoxinA Therapy in Patients with Refractory Overactive Bladder in Clinical Practice, Toxins 15(5): 338-251 (2023). [cited by applicant]
Luvisetto, et al. “Botulinum toxin type a as a therapeutic agent against headache and related disorders.” Toxins 7.9 (2015): 3818-3844. (2015). [cited by applicant]
Luvisetto, Botulinum Neurotoxins in Central Nervous System: An Overview from Animal Models to Human Therapy, Toxins 13: 751-767 (2021). [cited by applicant]
Malamed, et al., Intraoral Maxillary Nerve Block: an anatomical and clinical study, Anesthesia Progress, 30: 44-48 1983). [cited by applicant]
Melo-Carrillo, et al., Combined OnabotulinumtoxinA/Atogepant Treatment Blocks Activation/Sensitization of High-Threshold and Wide-Dynamic Range Neurons, Cephalagia, 41(1) 17-32 (2021). [cited by applicant]
Napier, et al., Supraorbital Nerve Block, StatPearls, pp. 7 (2023). [cited by applicant]
Nguyen, et al., Anatomy, Head and Neck: Face, StatPearls, pp. 10 (2023). [cited by applicant]
Niamtu, Local Anesthetic Blocks of the Head and Neck for Cosmetic Facial Surgery, III: Techniques for the Maxillary Nerve, Cosmetic Dermatology 17:645-647 (2004). [cited by applicant]
Patel, et al., Neuroanatomy, Spinal Trigeminal Nucleus, StatPearls, pp. 7 (2022). [cited by applicant]
Peterlin, et al., Post-Traumatic Stress Disorder in Episodic and Chronic Migraine, Headache 48:517-522 (2008). [cited by applicant]
Peterlin, et al., Post-Traumatic Stress Disorder in Migraine, Headache 49:541-551 (2009). [cited by applicant]
Robertson, et al., Critical analysis of the use of OnabotulinumtoxinA (botulinum toxin type A) in migraine, Neuropsychiatric Disease and Treatment 8:35-48 (2012). [cited by applicant]
Sendic, Greater Auricular Nerve, p. 3, KenHub at https://www.kenhub.com/en/library/anatomy/greater-auricular-nerve (2023). [cited by applicant]
Shafique, et al., Anatomy, Head and Neck, Maxillary Nerve, StatPearls, pp. 7 (2023). [cited by applicant]
Shone, et al., Peptide substrate specificty and properties of the zinc-endopeptidase activity of botulinum type B heurotoxin, Eur. J. Biochem 225: 263-270 (1994). [cited by applicant]
Stathakios, et al., Anatomy, Head and Neck, Neck Triangle, StatPearls, pp. 10 (2023). [cited by applicant]
Stathakios, et al., Anatomy, Head and Neck, Posterior Cervical Region, StatPearls, pp. 7 (2023). [cited by applicant]
Tajran J, Gosman AA. Anatomy, Head and Neck, Scalp. [Updated Jul. 25, 2022]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; Jan. 2023-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK5515… [cited by applicant]
Veerapaneni, et al., Trigeminal Neuropathy, StatPearls, pp. 15 (2023). [cited by applicant]
Yam, et al., General Pathways of Pain Sensation and the Major Neurotransmitters Involved in Pain Regulation, Int. J. Mol. Sci. 19: 2164-2186 (2018). [cited by applicant]
Yu, et al, SM. Anatomy, Head and Neck, Occipital Nerves. [Updated Oct. 31, 2022]. In: StatPearls [Internet]. Treasure Island (FL) : StatPearls Publishing; Jan. 2022-. Available from: https://www.ncbi.nlm.nih.gov/books/N… [cited by applicant]
Yu, et al., Anatomy, Head and Neck, Occipital Nerves, StatPearls, pp. 10 (2023). [cited by applicant]
Yu, et al., Anatomy, Head and Neck, Zygomatic, StatPearls, pp. 5 (2023). [cited by applicant]
Zito PM, Chauhan PR. Anatomy, Head and Neck, Supratrochlear. [Updated Jul. 25, 2022]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; Jan. 2022-. Available from: https://www.ncbi.nlm.nih.gov/book… [cited by applicant]
Zito, et al., Anatomy, Head and Neck, Supratrochlear, StatPearls, pp. 8 (2023). [cited by applicant]
EPO, Extended Search Report for European Patent Application Serial No. EP13760304.9 pp. 7 (Mar. 13, 2015). [cited by applicant]
WIPO, PCT Form ISA210, International Search Report for International Patent Application Serial No. PCT/US2013/000131, pp. 2 (Aug. 6, 2013). [cited by applicant]
WIPO, PCT Form ISA237, Written Opinion for International Patent Application Serial No. PCT/US2013/000131, pp. 5 Aug. 6, 2013). [cited by applicant]
WIPO, PCT Form IB373, International Preliminary Report on Patentability for International Patent Application Serial No. PCT/US2013/000131, pp. 7 (Sep. 16, 2014). [cited by applicant]
WIPO, PCT Form ISA210, International Search Report for International Patent Application Serial No. PCT/US2021/035736, pp. 3 (Sep. 27, 2021). [cited by applicant]
WIPO, PCT Form ISA237, Written Opinion for International Patent Application Serial No. PCT/US2021/035736, pp. 5 Sep. 27, 2021). [cited by applicant]
Mayo Clinic; https://www.mayoclinic.org/diseases-conditions/post-traumatic-stress-disorder/symptoms-causes/syc-20355967; accessed Apr. 11, 2025 (Year: 2024). [cited by applicant]
CNIPA, First Office Action for Chinese Patent Application Serial No. 2021800568395, pp. 6 (Mar. 13, 2025). [cited by applicant]
JPO, Notice of Reasons for Rejection for Japanese Patent Application Serial No. 2022-574396, pp. 11 (May 27, 2025). [cited by applicant]